A state laboratory in China procured 40 cynomolgus monkeys in June at 178,000 yuan ($26,294) each — nearly double the price paid a year earlier — in the latest sign of just how fast China's biotech research boom is outrunning the world's already-strained supply of lab primates.
How Fast Prices Have Climbed
The price surge has been dramatic and recent. According to Kaiyuan Securities analyst Yu Ruyi, cynomolgus (also called "crab-eating" or long-tailed) macaques fetched around 90,000 yuan ($13,301) in mid-2025; by June 2026, tender results from China's National Institute for Food and Drug Control put the price at 178,000 yuan. Less than two weeks later, a separate tender pushed the per-unit budget even higher, to 190,000 yuan (roughly $28,084) — meaning a single lab monkey now costs about as much as a mid-size sedan in China. Prices had actually fallen as low as 80,000-125,000 yuan in 2023-24 after an earlier pandemic-era spike cooled off, making the current run-up a sharp reversal rather than a steady climb.
What's Driving the Shortage
Analysts point to a structural mismatch between booming demand and inelastic supply. A wave of drug-licensing deals between Chinese biotech firms and global pharmaceutical giants, combined with a broader revival in pharmaceutical fundraising, has pushed a record number of candidate drugs into early-stage testing — and cynomolgus monkeys are essentially mandatory for the preclinical safety trials required before certain drugs can win regulatory approval. On the supply side, breeding capacity simply hasn't kept pace: raising a cynomolgus monkey to the 3-to-5-year age typically required for toxicity and safety studies takes roughly four years, meaning breeders can't quickly ramp up supply even as demand spikes. One analysis estimates the resulting annual shortfall at around 10,000 animals.
Why This Matters for China's Biotech Ambitions
The supply squeeze threatens to add delays to China's characteristically breakneck pace of drug development, given that monkey experiments remain a prerequisite for many drug approvals. Jefferies' Cui Cui, head of healthcare research for Asia, has tied the dynamic partly to global monetary conditions as well, noting that "US rate cuts have boosted biotech funding, so more projects are moving into early stages and need safety assessment — and that means more monkeys," pointing to a genuinely global demand pressure layered on top of China's own domestic R&D surge.
Winners and Losers in China's Markets
The price spike has produced sharp divergence among Chinese biotech-adjacent companies. Joinn Laboratories, which holds an inventory of roughly 30,000 monkeys, saw its shares hit the daily limit up after pre-announcing a nearly 14-fold surge in first-half net profit, dragging the broader contract research organization (CRO) sector higher with it. But that windfall has come at the direct expense of other CROs that must buy monkeys externally rather than draw from their own reserves — meaning the same price surge that's boosting monkey-holding companies is simultaneously squeezing margins for competitors reliant on the open market. In July 2026, China's A-share market saw a notable sector rotation, with capital shifting out of overheated tech stocks and into pharmaceutical names as the lab-monkey story gained investor attention.
A Global Pattern, Not Just a China Story
The current price pressure echoes a broader, years-long primate supply crunch that first emerged when China halted monkey exports at the start of the COVID-19 pandemic in 2020, sending U.S. prices from a few thousand dollars to $20,000 or more almost overnight — with the FDA saying prices have gone as high as $50,000 in some cases since. The U.S. National Institutes of Health-supported centers produced only about 5,000 monkeys domestically in FY2021, and cynomolgus-specific production has remained especially limited, underscoring that the underlying supply constraint is a global structural issue rather than one unique to China's current biotech boom.
What's Next
With breeding capacity structurally unable to expand quickly and demand continuing to surge on both sides of the Pacific, analysts expect lab monkey prices to remain elevated, and potentially climb further, in the near term. For China specifically, whether the country's biotech sector can sustain its rapid pace of drug development despite the primate supply squeeze — or whether the bottleneck begins to meaningfully slow approval timelines — is likely to be a key storyline for the industry through the rest of 2026.